2017
Epigenetic Regulations in the Pathogenesis of HCC and the Clinical Application
Puszyk W, Robertson K, Liu C. Epigenetic Regulations in the Pathogenesis of HCC and the Clinical Application. 2017, 69-93. DOI: 10.1007/978-3-319-68082-8_5.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseDevelopment of hepatocellular carcinomaHepatocellular carcinoma casesHepatocellular carcinomaHepatitis B virusHepatitis C virusRisk factorsChronic infectionNonalcoholic steatohepatitisViral hepatocellular carcinomaChronic cigarette smokingIndependent risk factorPathogenesis of hepatocellular carcinomaConsumption of excess caloriesLiver cancer casesFatty liver diseaseProgress to nonalcoholic steatohepatitisExposure to environmental factorsHCC casesLiver malignanciesConsumption of alcoholCancer casesB virusC virusLiver disease
2013
Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma
Puszyk W, Le Trinh T, Chapple S, Liu C. Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma. Laboratory Investigation 2013, 93: 983-990. PMID: 23917878, PMCID: PMC4028619, DOI: 10.1038/labinvest.2013.94.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaLate-stage hepatocellular carcinomaDevelopment of HCCAltered liver metabolismHepatitis B virusMajor risk factorProgression of HCCHepatitis CLiver functionB virusMicro RNA expressionRisk factorsLiver metabolismMetabolic organSurvival rateCancerRNA expressionCommon formCarcinomaUnderlying metabolic processesLiverExogenous environmental factorsEnvironmental factorsExcessive consumptionExposure
2011
Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience
Pan J, Oh S, Soldevila‐Pico C, Nelson D, Liu C. Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience. Clinical Transplantation 2011, 25: 164-170. PMID: 20156222, PMCID: PMC3480317, DOI: 10.1111/j.1399-0012.2010.01211.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCase-Control StudiesDNA, ViralFemaleFollow-Up StudiesGraft SurvivalHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoenzyme TechniquesLiver TransplantationMaleMiddle AgedPolymerase Chain ReactionPrevalenceRetrospective StudiesSurvival RateTissue DonorsTransplantation, HomologousTreatment OutcomeVirus ActivationConceptsHepatitis B virusDetectable HBV DNAHBV DNALiver allograftsLow prevalenceDe novo hepatitis B.Serum HBV DNA levelsHepatitis B core antigenHepatitis B surface antigenHBV DNA levelsSingle-center experienceB core antigenLiver biopsy tissueB surface antigenViral protein expressionHBV serologySeronegative recipientsHBV infectionHepatitis B.Such prophylaxisPositive donorsCore antigenRetrospective studyB virusProphylaxis
1994
Identification of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations.
Liu C, Mason W, Burch J. Identification of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations. Journal Of Virology 1994, 68: 2286-96. PMID: 8139013, PMCID: PMC236704, DOI: 10.1128/jvi.68.4.2286-2296.1994.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBase SequenceCell NucleusCells, CulturedDNA Mutational AnalysisDNA, ViralDNA-Binding ProteinsDucksEnhancer Elements, GeneticHepatitis B Virus, DuckHepatocyte Nuclear Factor 1Hepatocyte Nuclear Factor 1-betaLiverMolecular Sequence DataMutagenesis, Site-DirectedNuclear ProteinsPancreasProtein BindingTranscription FactorsConceptsHepatitis B virus enhancerVirus replicationDuck hepatitis B virus replicationHepatitis B virus replicationB virus replicationHepatitis B virusCore gene promoterLMH chicken hepatoma cellsHuman growth hormoneB virusLiver-enriched transcription factorsTwo- to fourfoldVivo effectsIntact viral genomeGrowth hormoneVirus enhancerPrimary hepatocyte culturesShort-term assaysProductive infectionSignificant inhibitionVirus RNA synthesisVirusCell linesHepatoma cellsFactor-binding sitesCharacterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus
Mason W, Cullen J, Saputelli J, Wu T, Liu C, London W, Lustbader E, Schaffer P, O'Connell A, Fourel I, Aldrich C, Jilbert A. Characterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994, 19: 398-411. PMID: 8294097, DOI: 10.1002/hep.1840190219.Peer-Reviewed Original ResearchConceptsHepatitis B virusDuck hepatitis B virusB virusInfected hepatocytesHigh doseHepatitis B virus infectionModerate liver injuryB virus infectionLong-term therapyAntiviral immune responseNucleoside analogue inhibitorsOvo infectionLiver injuryAntiviral therapyResidual virusChronic infectionAntiviral effectVirus infectionDrug treatmentImmune responseHistological evaluationMicrograms/Virus replicationTherapyInfection
1991
Characterization of the core promoter and enhancer of duck hepatitis B virus
Liu C, Condreay L, Burch J, Mason W. Characterization of the core promoter and enhancer of duck hepatitis B virus. Virology 1991, 184: 242-252. PMID: 1871970, DOI: 10.1016/0042-6822(91)90841-x.Peer-Reviewed Original Research